TUESDAY, April 30 (HealthDay News) -- Preteen girls may get the
same immune response against human papillomavirus (HPV) with two
doses of vaccine as young women get with the full three-shot
series, a new study suggests.
HPV is a sexually transmitted infection that causes cervical
cancer, the second biggest cancer killer in women around the
The HPV vaccine, approved by the U.S. Food and Drug
Administration in 2006, is given in a three-shot series. The first
and second doses are given one to two months apart, followed by a
third dose six months later.
Current government guidelines advise parents to vaccinate boys
and girls against HPV starting at age 11. That's partly to ensure
they're protected against HPV before their first sexual encounter,
but it's also to take advantage of biology.
"The immune response wanes with age. So the younger you are, the better immune response you have," said Dr. Jessica Kahn, a pediatrician at Cincinnati Children's Hospital Medical Center in Ohio. Kahn wrote an editorial on the study, but she was not involved in the research.
Although HPV vaccines are considered highly effective, fewer
than one-third of U.S. teens receive all three doses, according to
the U.S. Centers for Disease Control and Prevention's National
Immunization Survey of Teens.
Doctors have wondered if a different dosing schedule might save
money and time while still providing the protection of the
To find out, researchers in Canada, where vaccines are delivered
through school-based programs, randomly assigned 520 girls aged 9
to 13 to receive either two or three doses of the Gardasil vaccine,
which protects against four HPV strains. The girls who got two
doses got their shots six months apart. The girls who got three
doses got the vaccines on the regular schedule.
The younger girls were compared to 310 young women aged 16 to 26
who got three doses of the vaccine on the regular schedule.
Researchers took blood samples to measure the number of
antibodies made against each viral strain. They continued to take
blood samples over time to see how long the antibody response might
The younger girls who got two doses of vaccine appeared to make
at least as many antibodies against the HPV strains as the teens
and young women did on the three-dose regimen. And their protection
appeared to last just as long, up to three years after they started
their shots, according to the study, published April 30 in the
Journal of the American Medical Association.
The researchers cautioned that while the antibody response to
two doses of the vaccine looks promising, it doesn't prove that the
shorter course actually protected against viral infections or
cancers. A much longer study is under way to test that.
But study author Dr. Simon Dobson, a clinical associate
professor with the vaccine evaluation center at the University of
British Columbia, said the results are encouraging because they
suggest that younger girls could get two doses to prime their
immune systems against HPV, and then get a later dose to boost that
response closer to the time they might become sexually active.
"It raises the possibility that you could give two doses early in preadolescence, and then wait and give the third dose later in adolescence when the girls are going to be closer to the time when they're most likely to need protection against HPV," Dobson said.
Two doses would also save money, a key consideration especially
in countries where resources are scarce. According to the CDC, the
Gardasil vaccine cost about $130 a dose in 2012.
Until more is known, however, experts say girls should get all
Kahn said doctors don't know if two doses will be enough to
fully protect teenage girls.
"We need data on girls older than 13. Because even though the vaccine is recommended to be targeted to 11- to 12-year-olds, girls in the 13- to 17-year-old age range are actually most likely to be vaccinated. We would need to see data on immunogenicity or immune response in the 13- to 17-year-old age range," said Kahn.
And although protection from the vaccine appears to last a long
time, doctors still aren't sure how long, or whether three doses
might protect for longer than two.
"The data are encouraging, but it's really too soon to change recommendations based on the results of this one study," Kahn says.
For more on HPV vaccination, head to the
U.S. Centers for Disease Control and
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.